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ABSTRACT
Oct-4 is a POU domain transcription factor that is
critical for maintaining pluripotency and for stem
cell renewal. Previous studies suggest that trans-
cription regulation by Oct-4 at particular enhancers
requires the input of a postulated E1A-like cofactor
that is specific to pluripotent cells. However, such
studies have been limited to the use of enhancer
elements that bind other POU-protein family mem-
bers in addition to Oct-4, thus preventing a ‘clean’
assessment of any Oct-4:cofactor relationships.
Other attempts to study Oct-4 functionality in a
more ‘stand-alone’ situation target Oct-4 transac-
tivation domains to DNA using heterologous binding
domains, a methodology which is known to generate
artificial data. To circumvent these issues, analtered-
specificity binding Oct-4 (Oct-4RR) and accom-
panying binding site, which binds Oct-4RR only,
were generated. This strategy has previously been
shown to maintain Oct-1:cofactor interactions that
are highly binding-site and protein/binding confor-
mation specific. This system therefore allows a
stand-alone study of Oct-4 function in pluripotent
versus differentiated cells, without interference
fromendogenousPOUfactorsandwithminimaldevi-
ation from bound wild-type protein characteristics.
Subsequently, it was demonstrated that Oct-4RR
and the highly transactive regions of its N-terminus
determined here, and its C-terminus, have the
same transactivation profile in pluripotent and dif-
ferentiated cells, thus providing strong evidence
against the existence of such a pluripotent cell-
specific Oct-4 cofactor.
INTRODUCTION
Mouse Oct-4 is a member of the POU domain transcription
factor family with an expression pattern that is restricted to
pluripotent and totipotent cells of the animal and embryonic
stem (ES) and carcinoma (EC) cell lines (1–3). Treatment of
the pluripotent P19 EC cell line with the retinoic acid
(RA) morphogen stimulates cell differentiation with a parallel
downregulation in Oct-4 expression (1). (For the purposes
of simplicity, cell lines which are not generally considered
pluripotent, such as P19 cells which have been treated with
RA, or HeLa and NIH3T3 cells, shall henceforth be referred
to as differentiated cells). Oct-4 is critical for the mainten-
ance of cell pluripotency and for stem cell renewal. P19 cells
differentiated by fusion to ﬁbroblast cells can undergo
de-differentiation in response to ectopic Oct-4 expression,
while exogenous expression of Oct-4 in Oct-4-knockout
cells is also sufﬁcient to rescue pluripotency (4,5). Conversely,
embryos in which Oct-4 expression is knocked out fail to
maintain pluripotency within the inner cell mass (6).
A widely studied system forexamining Oct-4 function isthe
6W enhancer element, which is based on an immunoglobulin
heavy chain (IgH) enhancer and contains multimerized Oct-
protein binding sites (the consensus octamer motif is
ATGCAAAT ), as well as a b helix–loop–helix (bHLH) bind-
ing motif. This element is associated with a high level of
downstream reporter gene transactivation in pluripotent EC
cells which ordinarily express Oct-4, such as undifferentiated
P19 (P19U) cells (7,8), but importantly not in non-Oct-4
expressing, differentiated cell lines, when Oct-4 is expressed
exogenously (5–9). As 6W activity is dependent on functional
octamer motif (8) and as Oct-4 is the only known POU tran-
scription factor speciﬁc to undifferentiated P19 cells, Oct-4
has been proposed as a likely candidate for involvement in
undifferentiated cell-speciﬁc 6W activity. This suggestion has
been strengthened by the observation that antisense Oct-4,
but not antisense Oct-1, results in a relative drop in the activity
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Taken together, the above observations suggest the existence
of a cell-speciﬁc transcription cofactor, present only in undif-
ferentiated cells, which might also speciﬁcally interact with
Oct-4.
While attempts to identify such a cell-speciﬁc cofactor have
not yet been successful, a few interesting observations have
been made which provide some evidence for an Oct-4:cofactor
paradigm. For example, Oct-4 has been shown to interact
with the adenovirus protein E1A, resulting in transcriptional
upregulation from ‘distal’ 6W enhancer positions. Further-
more, an E1A-like protein is thought to exist in undifferenti-
ated P19 cells, although again it has not yet been identiﬁed
(8–10). It is perhaps therefore not surprising that the hypo-
thesized E1A-like factor and postulated Oct-4 cofactor are
often suggested to be the same thing. The relevance of any
Oct-4:E1A relationship is unclear however, as E1A has been
shown to interact with DNA in a non-speciﬁc manner and is
thought to be able to directly regulate transcription through the
TATA box and TBP or TAFs as well as numerous additional
transcription factors and cofactors [reviewed in (11,12)].
The observation that the papillomavirus protein E7 can also
function as an Oct-4 transcription cofactor may further suggest
a common Oct-4 cofactor paradigm (9). Indeed, others have
drawn on a number of Oct-4 studies as well as their own work
to propose a theoretical model in which a certain subset of
Oct-4 genes, which are ‘squelched’ by over-expression of
Oct-4, require a cofactor(s) which in circumstances of high
nuclear Oct-4 concentrations may be sequestered away from
the Oct-4:DNA complex (13,14). However, this cofactor
model is only suggestive of the existence of Oct-4 cofactors
and not that such factors are particular to pluripotent cells and
an Oct-4 partnership.
Studies of Oct-4 functionality in pluripotent cells to date
have focused on the use of Oct-4 activation domains fused
to heterologous binding domains, such as the GAL4 DNA-
binding domain, or through an endogenous Oct-4-knockout
system for which complementation by various Oct-4 mutants
allows determination of functional domains (5,15). Such sys-
tems have demonstrated that both Oct-4 N- and C-terminus
activation domains contribute to Oct-4 functionality. How-
ever, fusion proteins comprising heterologous DNA binding
motifs, although representing the only effective route for the
analysis of cell-speciﬁc activity without contributions from
the endogenous protein, are known to generate data that are
not representative of true wild-type protein function. This
therefore suggests that the Oct-4 DNA-binding domain con-
tributes to functional activity and that intra protein structure or
a particular Oct-4 binding conﬁguration is essential for correct
transcription regulation by Oct-4 (15).
An alternative and more elegant route is that employed
by Pomerantz and Sharp (16), who showed that by chang-
ing amino acids Valine-47 and Asparagine-51 within the
POU homeodomain of Oct-1 to arginine residues, the pro-
tein (Oct-1RR) would bind a mutated octamer element
ATGCAAGG with a signiﬁcantly higher efﬁciency than the
wild-typeprotein.Importantly,theOct-1RRproteinretainsthe
ability to interact with the Herpes simplex virus coactivator
VP16 and the cellular protein Host cell factor, in a manner
analogous to that of wild-type protein, which has been
shown to be highly dependant on the conformation of
promoter-bound Oct-1 (17). Other studies have shown
that both Oct-1RR and Oct-2RR can functionally replace
Oct-1/2 in the interaction with the B-cell speciﬁc coactivator
Bob-1, again conﬁrming the structural and functional integrity
of the modiﬁed Oct-protein–DNA complex (18). Translating
this altered-speciﬁcity binding strategy to Oct-4 would there-
fore maintain any wild-type protein/binding conﬁguration that
could be essential for proper protein function, while elimin-
ating any endogenous protein contributions in functional
assays.
Here,weemployanaltered-speciﬁcitysystemincorporating
the double amino acid substitution Oct-4 (Oct4RR), which
alters Oct-4 DNA binding speciﬁcity to the sequence 50-
ATGCAAGG-30. We demonstrate that this sequence is not
bound efﬁciently by wild-type Oct-4 or other POU domain
proteins, thus eliminating the contribution of endogenous pro-
teins in functional assays to enable a ‘stand-alone’ assessment
of Oct-4 transcriptional regulation and potential use of cofac-
tors. Data presented here show that Oct-4RR has an equivalent
transactivation proﬁle in pluripotent and differentiated cells,
thus challenging the current hypothesis that Oct-4 utilizes a
pluripotent cell-speciﬁc cofactor on such regulatory elements.
Activation domain deletions in concert with altered-speciﬁcity
binding mutants were also constructed and used to assess any
cell-speciﬁc requirement for particular Oct-4 subdomains.
Oct-4-mediated transactivation was also shown to be predom-
inantly a function of the N-terminus activation domain, with
the C-terminus activation domain displaying a lower but still
signiﬁcant transactivation function, again with neither activa-
tion domain displaying any cell speciﬁcity.
MATERIALS AND METHODS
General reagents and chemicals
General chemicals were supplied by Sigma Aldrich, Invitro-
gen, ICN, VWR, Amersham Pharmacia or Scientiﬁc and
Chemical Supplies unless otherwise stated.
Cell culture and transfection
NIH3T3, HeLa and COS cells were maintained in DMEM
media supplemented with 10% fetal calf serum. P19 cells
were maintained in DMEM supplemented with 2.5% FCS
and 7.5% new-born calf serum. All media contained penicillin
and streptomycin. Undifferentiated P19 cells were induced to
differentiate with 0.5 mM all-trans RA for 4 days prior to
transfection (19).
Unless otherwise stated, transfections were performed on
cell densities of  30% conﬂuence for undifferentiated P19
cells (seeded at 5 · 10
5 cells per 5 cm dish), and 60% con-
ﬂuence for RA-treated P19 cells (seeded at 5 · 10
5 cells) and
NIH3T3 cells (seeded at 6 · 10
5 cells per 5 cm dish). For 5 cm
dishes: after overnight growth of seededcells, the medium was
changed 2 h prior to transfection and DNA mixtures were
prepared and added to individual cell culture dishes using
the BES CaPo
4  method of transfection; speciﬁed plasmid
DNAs were balanced for DNA concentration using both
UV spectrophotometry and agarose gel analysis and the
same batch of BES was used throughout these studies from
frozen aliquots. An aliquot of 0.5 mg of EﬂacZ was included in
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fection efﬁciency. Empty EFplink vector was used to balance
DNA concentration in each transfection experiment. Cells
were harvested after 48 h for analysis.
Oligonucleotides and plasmid construction
Oligonucleotides used in plasmid construction and electro-
phoretic mobility shift assay (EMSA) were as follows.
Site-directed mutagenesis. POU domain substitutions >
4POUN-R: GTATGGTTCTGTAGGCGGCG-CCAGAAGG.
4POURR: GATGTGGTTCGAAGATGGTTCTGTAGG. Oct-4
deletions > N-termD61–90(forOct-47–17amino aciddeletion):
+GGCTGGAC-ACCTGGCTGGGGGTGATGGG,  CCCA-
ACCCCCAGCCAGGTGTCCAGCC. Oct-4 Nco/Bsu join:
(+) CATGGCTGGATGTGGACC, ( )TGAGGTCCACAT-
CCAGC, (ii) TCAGGTCCACATCCAGC. (Nco/Bsu join +
was duplexed with both Nco/Bsu join   and Nco/Bsu
join II   which correspond to duplexes used to produce
D4–70 and D4–89 Oct-4 proteins, respectively).
EMSA and cloning target binding sites. H2B: +CTAG-
AAGAATCGCTTATGC AAATAAGGTGAAGAT,  CTA-
GATCTT-CACCTTATTTGCATAAGCGATTCTT. VkGG:
+ TCGATGAGGGTATGCAAG-GTATTAAG,  TCGA-
CTTAATACCTTGCATACCCTCA. VkGT: + TCGATGA-
GGGTATGCAAGTTATTAAG,  TCGACTTAATAACTT-
GCATACCCTCA. SEQUENCING >M13 ( 40) forward
(for pBLCAT-based vectors): GTTTTCCCAGTCACGA.
Oct-4POU (for Oct-4 POU domain mutations in any vector):
CTAGCATTGAGAACCGTGTG > EFplink forward: TTG-
CTTA-CATTTGCTTCTG. EFplink reverse: CCAGGGC-
ATTAGCCACAC.
Plasmid construction
Oct-4cDNA was provided by Rosner et al. (2) in pCMVOct-4.
Oct-1RR was provided by H. Singh, Howard Hughs Medical
Institute, University of Chicago. PBLCAT was provided by
Luckow and Schutz (20). EFplink vector is described else-
where (21). pEFLacZ: b galactosidase gene inserted into
EFplink for constitutive expression and was kindly provided
by S. Walker, Ribotargets Ltd, Cambridge, UK. EVRF0 and
pPOU6Vp16 were provided by D. Meijer (22). All plasmid
constructs were conﬁrmed via sequencing and protein expres-
sion studies were performed where appropriate. CAT repor-
ters > p6WCAT: Multimerized IgH 1W site (6W) inserted
105 bp upstream of minimal TK-promoter TATA box and
linked CAT gene. 6W element from pLI4-6xIgH [provided
by M. Gstaiger (23)] was ligated into the SalI site of pBLCAT.
Constructs were selected where octamer sequence of the
1W elements were orientated 50–30 on the DNA bottom
strand upstream of CAT gene. pVkGGCAT and pVkGTCAT
GTCAT series: single oligonucleotides corresponding to a
variable k-immunoglobulin promoter element with an AT
to GG mutation in the octamer motif (VkGG) or AT to GT
(VkGT) were ligated into the SalI site in pBLCAT to produce
a six-site insertion (p6VkGGCAT) or seven-site insertion
(p7VkGTCAT), respectively. p6VkGGCAT was reopened
with SalI, and the ligation process was repeated to produce
a eleven-site insertion into pBLCAT (p11VkGGCAT). Oct-4
expression plasmids > pEFOct-4: Oct-4 cDNA from
CMVOct-4 was generated by NcoI and EcoRI digestion
and ligated into NcoI–EcoRI EFplink to generate an in-
frame fusion to the vector Myc epitope sequence. pEFOct-
4DN: an AvaI digest of an Oct-4 cDNA was blunt ended by
Klenow polymerase ﬁll-in and ligated into SmaI digested
EVRF0 to give an N-terminal deletion of sequence corres-
ponding to amino acids 1–105. This Oct-4 sequence was
moved into EFplink using a BamHI/XbaI digestion.
pEFOct-4DC: an EarI partial digest of Oct-4 cDNA in
EfOct-4 was Klenow blunt ended and elucidated with NcoI
corresponding to 50 of Oct-4 coding sequence. Fragments were
then ligated into NcoI sticky/EcoRI Klenow blunt-ended
EFplink to produce clones containing Oct-4 cDNA with dele-
tion of sequence corresponding to amino acids 285–352.
pEFOct-4N-R Oct-4 (N51R mutation in the POU homeodo-
main): an EcoRI Oct-4 cDNA from CMVOct-4 was inserted
into pGEM-3Zf( ) from Promega Inc., where the vector Pst1
site had been removed, XbaI and SpHI, followed by Klenow
ﬁll-in of 50 overhangs and ‘chewing’ of 30 overhang to create
blunt ends (using T4 polymerase) respectively,withreligation.
The resulting plasmid was named pGEMOct-4 and used to
make single-stranded bromoxyuridine DNA in the F+ E.coli
strain CJ236 which was subsequently used for mutagenesis
with the POUN-R oligonucleotide. A fragment comprising a
450 bp PstI–NarI fragment encompassing the mutant region
was swapped back into pGEMOct-4 to make pGEMOct-4N-R.
The Oct-4 carrying the desired mutations was then swapped
into EFplink in-frame with the vector myc epitope sequence
via an NcoI/EcoR1 digest. pEFOct-4RR: as above but using
POURR oligonucleotide to mutate pGEMOct-4N-R. pEFOct-
4RRDN: an AvaI EFOct-4RR fragment was Klenow blunt-end
ﬁlled and inserted into EFplink (Dam ) cut with ClaI and
Klenow blunt-end ﬁlled and dephosphorylated. Selected
clones contained Oct-4 with deleted sequence corresponding
to amino acids 1–105. pEFOct-4RRDC: the truncation Oct-4
from pEFOct-4DC (see above) was swapped with the full-
length Oct-4 coding sequence into pGEMOct-4 via a NcoI/
EcoRI digest making pGEMOct-4DC. Subsequently, a PstI–
NarI fragment from EFOct-4RR comprising the mutant part of
the binding domain was swapped into the new pGEMOct-4DC
to make pGenOct-4RRDC. This construct was then used to
swap the truncation Oct-4RR sequence into EFplink via an
NcoI/EcoRI digest. pEFOct-4RR D7–17: the complementary
oligonucleotides Oct-4:7–17 were used. Employing these
oligonucleotides, EFOct-4RR was used in the Quickchange
mutagenesis kit supplied by Stratagene to produce an Oct-4
mutation with amino acids 7–17 deleted. pEFOct-4RRD2–29:
EfOct-4RR was cut at the 50 Oct-4cDNA NcoI and an BamHI
internal to Oct-4 cDNA and Klenow blunt-end ﬁlled. The
resulting digest was religated and clones were selected
which contained the Oct-4 sequence which corresponded to
deletions of amino acids 2–29. pEFOct-4RRD4–70: the oligo-
nucleotide duplex for Oct-4 D4–70 was used which had
50 Nco1 and 30 Bsu36I ends corresponding only to Oct-4
Bsu36I site at codon 70 of Oct-4 sequence. EFOct-4RR
was partially digested with Bsu36I, which shows site degen-
eracy (cutting at Oct-4 positions 259, 310 and 1056) and NcoI
corresponding to the Oct-4 50 translation start site. The
resulting digest of the correct length was dephosphorylated
and used in a ligation with phosphorylated double-stranded
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oligonucleotide duplex Oct-4 D4–88 used here corresponding
only to 50 Nco1 and 30 Oct-4 Bsu36I site at codon 88 of Oct-4
sequence. pEFOct-4RRDC (7–17, 2–29, 4–70 and 4–88). As
above but using pEFOct-4RRDC as substrate.
Protein expression and binding analysis
Protein extracts. For whole cell protein extracts, frozen
cell pellets were placed on ice and resuspended in 2–3 cell
pellet volumes of cold whole cell extract buffer (10 mM
HEPES, pH 7.9, 0.4 M NaCl, 0.1 mM EGTA, 0.5 mM DTT,
5% glycerol and protease inhibitors: 10 mg/ml APMSF,
2 mg/ml Aprotinin, 3 mg/ml Antipan, 4 mg/ml Bestatin,
6 mg/ml Chymostatin, 3 mg/ml E-64, 1 mg/ml Leupeptin
and 1 mM phenylmethylsulfonyl ﬂuoride). Following 15 min
incubation on ice, the samples were microfuged at high speed
at 4 C and the supernatant was processed and stored at  70 C.
For cell nuclear extracts, pellets were resuspended on ice in
10 mM HEPES, pH 7.9, 0.1 mM EDTA, 0.1 mM EGTA,
10 mM KCl and 0.5 mM DTT. After 5 min incubation on
ice, NP-40 was carefully added to 0.5% and left for a further
10 min on ice. The homogenate was microfuged for 1 min
at mid-speed and the supernatant was removed from the pel-
leted nuclei. The nuclear pellet was then washed in buffer
minus NP-40 and pelleted again. Washed pelleted nuclei
were then treated with mammalian whole cell extract buffer
as speciﬁed above. Prior to EMSA assays or the addition of
SDS loading buffer for western blots, supernatants were
measured for protein concentration using the BioRad DC
system.
Western blots. Typically 60 mg of denatured protein extract
was electrophoresed through a 12% SDS polyacrylamide
gel onto nitrocellulose membrane. The transferred gel was
stained with Coomassie blue to check that transfer had been
successful and to conﬁrm protein loading. Blots were pro-
cessed according to antibody manufacturer’s conditions
with use of horseradish peroxidase (HRP)-conjugated second-
ary antibody against primary. Visualization of HRP-driven
chemiluminescence was undertaken using X-ray ﬁlm and a
PhosphorImager.
EMSA. Oligonucleotide concentration and integrity was
conﬁrmed on an agarose gel prior to use. Complementary
oligonucleotides were annealed according to the standard
procedures, and double-stranded complexes were precipitated
and redissolved in water and DNA concentration measured on
a UV spectrophotometer. Oligonucleotide duplexes were also
validated on an agarose gel prior to further use. An aliquot
of 100 ng of oligonucleotide duplex was radiolabelled using
Klenow polymerase and [a-
32P]dCTP to ﬁll-in 50 overhangs
according to standard protocols. G50 sephadex resin spin
columns were used to extract unincorporated nucleotide. Typ-
ically, 12 mg of whole cell or 30 mg of nuclear extract protein
and 2 mg poly(dI–dC), poly(dG–dT) or denatured salmon
sperm DNA as speciﬁed was included in 20 ml reactions
with 0.75 ng labelled probe and incubated for 30 min at
room temperature in 1· EMSA buffer (50 mM HEPES,
pH 7.9, 100 mM NaCl, 20% Glycerol, 400 mg/ml BSA,
0.1% NP-40, 2 mM DTT and 2 mM EDTA). For supershift
experiments, antibody was added to reactions after 20 min
and incubated at room temperature for a further 10 min.
The reaction mixture was analysed on a 4% non-denaturing
polyacrylamide (19:1) gel. Protein–DNA complexes were
visualized after autoradiography with or without intensifying
screens at  70 C overnight and/or on a PhosphorImager
after a 3–16 h exposure.
For competition binding assays and determination of
relative apparent dissociation constants (Kd), gel retardations
were performed as follows: 0.5 ng of labelled oligonucleotide
was added to increasing amounts of cold competitor DNA as
speciﬁed along with 2 mg poly(dI–dC) in 1· EMSA buffer. At
T0, a constant protein extract amount was added to reaction
tubes on ice, making a ﬁnal reaction volume of 20 ml, and
incubated at room temperature for 30 min.
Transcriptional activation analysis
The following protocols were performed on experimental sets.
Protein extraction. Freeze-thaw lysis was the chosen
method of cell disruption for CAT and b-Gal assays. Super-
natants were assayed for protein concentration using the
DC BioRad protein assay according to the manufacturer’s
instructions.
The b-galactosidase activity assay. Aliquots containing
100 mg of each cell extract protein sample within an experi-
ment set were aliquoted into separate wells of a microtitre
plate and assayed for internal-control b-gal activity. b-gal
buffer was mixed with OMPG at a ratio of 4:1, and 250 ml
of this mixture was added to individual wells of the microtitre
plate containing cell extract aliquots on ice using a 12-tip
multipipette to eliminate reaction start-time asynchrony.
The microtitre plate was subsequently incubated at 37 C.
Using a plate reader set to measure optical density at a wave-
length of 420 nm, the microtitre plate reactions were mon-
itored at regular time intervals so that optical density did
not fall outside of a time versus optical density (OD) linear
relationship. The ﬁnal value for b-gal activity within an
experimental set was calculated by dividing OD420 by
time (min) and then multiplying by 100. Such b-gal readings
were used as an internal control for normalization of trans-
fections or as a guide for the interpretation of results of
CAT assays.
CAT assays. A maximum of 70% of whole cell protein extract
per transfection plate derived through the freeze thawing pro-
cess was used in CAT assays for each transfection. b-gal
readings for individual transfection reactions were either
used to normalize transfections within an experiment as spe-
ciﬁed in results, or used as a guide for interpretation of results
of CAT assays performed for measurement of the transcrip-
tional activity of particular transcription factor systems.
Experiments that were not normalized according tob-gal read-
ings were normalized for protein concentration. Acetylation
of
14Cchloramphenicolfollowed by thin-layerchromatography
was the method chosen for ascertaining CAT enzyme con-
centrations and was performed according to the standard
protocols. TLC plates were subsequently analyzed using a
Fuji FLA2000 PhosphorImager and data analyzed using
Aida software.
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AlteredspecificityOct-4bindsamutanttargetsitewhich
itself is not efficiently bound by wild-type Oct-4
Oct-4 and Oct-1 share signiﬁcant sequence homology in their
DNA-binding domains and are known to bind very similar
motifs within subsets of their respective target genes. It has
been previously shown that mutations in the DNA-binding
domain of Oct-1 (Oct-1RR) alters its sequence speciﬁcity,
enabling it to bind efﬁciently to two artiﬁcial recognition
sites, ATGCAAGG (GG site) and ATGCAAGT (GT site).
Importantly, both sites were shown to bind wild-type protein
with a relatively low afﬁnity, albeit with the former site dis-
playing a relative 130-fold lower afﬁnity for wild-type Oct-1
that the latter but the GT site having a relatively higher afﬁnity
for Oct-1RR (16). We have transposed these mutations to
Oct-4, creating an Oct-4RR (V47R, N51R) mutant and imbed-
ded altered-speciﬁcity binding sites into promoter construct
to enable exclusion of wild-type Octamer factor contributions
in Oct-4 functional studies (Figure 1A and B).
Either GG or GT sites were included in a 25 bp immuno-
globulin variable k-light chain (IgVk) enhancer element
situated on the pBLCAT reporter vector, replacing the single
consensus octamer site. (These sequences were designated
VkGG and VkGT, respectively). This enhancer element con-
tains no other recognized protein binding sites according to
the database analysis but has been shown to maintain a highly
binding conformation sensitive partnership between the B-cell
speciﬁc cofactor Bob-1 and the altered-speciﬁcity binding
Oct-2RR protein (18). Octamer expression constructs used in
this study are shown in Figure 1A.
The plasmids EFOct-N51R and EFOct-4RR, along with
EFOct-4 (wild-type), were transiently transfected into
NIH3T3 cells. Whole cell extracts, normalized for Oct-4 pro-
tein concentration via western blot analysis (Figure 1C), were
then used in EMSA experiments with respective target binding
sites (Figure 1D). As seen in Figure 1D, binding of Oct-4RR
and Oct-4N51R to the wild-type octamer motif ATGCAAAT
(Histone 2Bpromoter-basedprobe)was similar tothat seenfor
wild-type Oct-4. Conversely, however, wild-type Oct-4 bound
only very weakly to the VkGG site, compared with Oct-4RR
and Oct-4N51R and in comparison with binding to the wild-
type site (Figure 1D, lanes 2–4 compared with lanes 7–9). The
relative reduction in binding activities between wild-type and
VkGG sites, which was  200-fold, 20-fold and 4-fold for
wild-type Oct-4, Oct-4N51R and Oct-4RR, respectively, sug-
gests that binding of Oct-4RR to VkGG sites is signiﬁcantly
higher than for Oct-4N51R binding to the same site.
As can be seen in Figure 1D (right hand panel), Oct-4RR
binds more strongly to VkGT than to VkGG sites (lane 70
compared with lane 120). However, unlike for the VkGG site,
wild-type Oct-4 also binds signiﬁcantly to the VkGT site
(Figure 1D, lane 20 compared with lanes 60 and 100). Wild-type
Oct-1, similarly to Oct-4, also bound more strongly to VkGT
than to VkGG sites, although this was only obvious after over-
exposure of the EMSA gel. Oct-1RR was included as a control
and mirrored Oct-4RR binding data in terms of the relative
afﬁnities for wild-type and altered-speciﬁcity sites, in com-
parison with wild-typeprotein(Figure1D,lanes40,8 0 and 130).
In order to obtain more quantitative binding data describing
the difference in afﬁnities for wild-type and mutant proteins
for their respective recognition sites, oligonucleotide competi-
tion binding assays were performed. Figure 1E shows the
binding curves obtained using whole cell extracts in which
Oct-4 and Oct-4RR had been over-expressed. The relative
binding afﬁnity of Oct-4RR for the VkGG site was shown
to be  2-fold lower than the afﬁnity of Oct-4 for the wild-type
octamer site. This, along with evidence of poor binding of
endogenous protein to the VkGG site, suggested to us that
we could conﬁdently undertake functional studies of Oct-4
usingthe altered-speciﬁcitysystem.TheGGsitewasprimarily
chosen for further study with Oct-4RR, although the GT site
was also used as the functional relevance of higher wild-type
proteinbinding was unknownand as it resembled the sequence
ATGCTAGT, a natural target for Oct-4 found in the UTF-1
gene enhancer element (24).
Transiently expressed Oct-4RR, but not endogenous or
exogenous Oct-4, promotes gene expression through the
altered-specificity binding sites
The functionality of monomeric Oct-4RR was demonstrated
as a ‘stand-alone’ transcription factor in undifferentiated
(‘pluripotent’) P19 cells using VkGG (in p6VkGGCAT) and
VkGT (in p7VkGTCAT) site-containing reporter constructs
(Figure 2A and B). Relative transactivation of CAT reporter
gene above basal activity was measured at 10-fold for
Oct-4RR/VkGG and 5-fold for Oct-4RR/VkGT protein/
reporter vector combinations, which was consistent with the
binding data presented here (Figure 1D). No transactivation
was demonstrated in the absence of target sites (pBLCAT
vector). Importantly, over-expression of wild-type Oct-4
was not associated with transactivation through either binding
site. However, given the higher afﬁnity binding of the Oct-4
mutant proteins and wild-type Oct-4 for VkGT over VkGG
probes, these results were unexpected to some degree and may
indicate greater interference from endogenous POU proteins
in vivo or a functionally sub-optimal protein–DNA confor-
mation speciﬁc to the VkGT site. Transcriptional activation
associated with the 6W element (in p6WCAT), which contains
the wild-type octamer motif, was over 40-fold that of empty
reporter vector (pBLCAT) and signiﬁcantly higher than
described above for Oct-4 mutants through VkGG and
VkGT sites. This suggests that promoter context or structural
conformation may be important in presenting optimal Oct-4
transactivation function. Consistent with binding data,
Oct-4N51R displayed at least half the transcriptional activity
as Oct-4RR in all cases and was therefore not studied in
any greater detail. The non-optimal VkGT site was also
withdrawn from further detailed studies.
Oct-4RR activates transcription to an equivalent
amount in undifferentiated and differentiated
P19 cells through VkGG sites
To assess any relative differences in Oct-4RR transactivation
potential between undifferentiated (P19U) and differentiated
P19 (dP19) cells, a range of expression vector concentrations
were used in transient transfection experiments. Oct-4RR
activates reporter gene expression in both P19U and dP19
cells to a comparable degree (Figure 3D). For both cell states,
the maximum transcriptionalactivity associated with Oct-4RR
was at low vector concentrations (100–250 ng range). Total
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6016 Nucleic Acids Research, 2005, Vol. 33, No. 18amounts of transfected DNA were equivalent for all transfec-
tion experiments. Western blot and EMSA analysis showed an
approximate 3- to 4-fold higher concentration of Oct-4RR per
mg of protein in dP19 compared with P19U cell extracts
(Figure 3A and B). This reﬂects the relative transfection efﬁ-
ciencies of P19U and dP19 cells (25 and 42%, respectively)
and is conﬁrmed by control b-galactosidase (b-Gal) data
(Figure 3D). (Transactivation was measured against internal
controls within each experiment, allowing accurate compar-
ison of transactivation levels between each cell type).
Importantly, transient Oct-4RR concentrations studied in
these experiments matched endogenous Oct-4 protein levels
within the optimal range of vector concentrations used in
functional studies, and thus can be considered as physiologic-
ally relevant (see Figure 3C).
EMSA data conﬁrmed the presence of endogenous Oct-4
in P19U cells and that its expression was extinguished
following cell differentiation (Figure 3B). In accord with pre-
vious studies (9), the transactivity associated with the 6W
enhancer, which contains the consensus octamer motif, was
relatively high in P19U cells, compared with differentiated
cells which have been transfected with Oct-4 expression vec-
tor (Figure 3D and E). The 6W enhancer therefore demon-
stratesaclear cell-speciﬁcactivitywhich isnotseenforVkGG
sites in response to Oct-4RR expression.
Oct-4RR N-terminus remains the predominant
activation domain through differentiation
The next experiment set out to determine which regions of
Oct-4 are the most important for transactivation function in
pluripotent cells and whether such ‘activation domains’ func-
tion similarly in differentiated cells. Using existing informa-
tion on Oct-4 protein structure, extensive Oct-4RR C- and
N-terminus activation domain deletions were constructed
and used in cotransfection experiments with appropriate
reporter vectors (Figure 4). Primary analysis of CAT data
revealed no cell-speciﬁc activation domain usage (Figure 5).
Further data analysis indicated that in an Oct-4-native, pluri-
potent environment and in a differentiated cellular environ-
ment, the N-terminus is the more powerful of the Oct-4
activation domains in a stand-alone situation, while the
C-terminus displayed a lower but still signiﬁcant transactivity
(Figure 5A). Protein expression and competition binding
assaysindicatedthat proteinconcentration and binding afﬁnity
of each deletion mutant were approximately equal and there-
fore not a contributing factor in the differing transactivation
levels seen here (Figure 5B). Importantly, the same deletions
of wild-type Oct-4, when assayed using a wild-type site-
containing reporter construct, display equivalent transactiva-
tion proﬁles to those of Oct-4RR deletion experiments
(Figure 5C, i). This result suggests that no fundamental struc-
tural or functional change is occurring in the Oct-4 mutant
proteins, as a consequence of modiﬁcation of their DNA-
binding domains.
To determine whether there was any cell-speciﬁc usage of
subregions of the more powerful N-terminus activation
domain, a series of truncation proteins were constructed
where deletions of increasing size from the 50 end of the
N-terminus were introduced (Figure 4). Such truncation
proteins were also studied with and without intact Oct-4
C-terminus in order to determine whether there was any
dependence on the C-terminus activation domain for Oct-4
function. Inference from the results of N-terminus deletions
of amino acids 1–28, 7–17 and 3–70, shown in Figure 6,
suggests that the N-terminus subdomain containing amino
acids 28–70 is essential and sufﬁcient for full N-terminus
Oct-4 activity, while again exhibiting no cell-speciﬁc pre-
ference. Deletion of the C-terminus caused a drop in trans-
activity across the board, which was consistent with previous
data showing that this domain possessed a signiﬁcant non-
cell-speciﬁc transactivation function. No dependence on the
C-terminus was exhibited by any of the active N-terminus
domains.
DISCUSSION
Using an altered-speciﬁcity binding strategy, it is demon-
strated here that Oct-4RR as a ‘stand-alone’ transcription fac-
tor displays the same transactivation proﬁle in both pluripotent
and differentiated cells, thus casting doubt over a previously
hypothesized functional partnership between Oct-4 and an
unidentiﬁed pluripotent cell-speciﬁc transcription cofactor
in such a promoter context. The possibility that any potential
cofactor interaction might be highly sensitive to binding con-
text or subtle changes in binding conformation, and is thus not
observed when using non-wild-type Oct-4, must be acknow-
ledged. However, given the overall homology of the 4RR POU
domain to that of wild-type protein and evidence for equival-
entfunctionalitytowild-typeproteinshownhere,thisexplana-
tion is unlikely.
Despite the longstanding postulated existence of an Oct-4
cofactor speciﬁc to pluripotent cells (8,9,13), there is as yet no
evidence presented which identiﬁes such a factor, although
Figure 1. Bindingofwild-typeOct-4,Oct-4N51RandOct-4RRtoaltered-specificitybindingsitesVkGGandVkGT.(AandB)Mutantbindingdomainsandtarget
sites are detailed. (C) COS cells were transfected with 3 mg of indicated plasmids. Western blots were performed in duplicate using mouse antibody against the
myc epitope, which was fused to the N-terminus of all the proteins. (D) Using protein expression data from western blots, Oct-4-type expression was
normalized and a maximum of 12 mg of protein extracts were used in each EMSA reaction for lanes 1–10 and 10–130 and a maximum of 24 mg of protein
for lanes 10–14. In lane 5 (asterisk), 12 mg of HeLa cell extract for an EFOct-4 transfection replaces COS cell extract. Each reaction also included 2 mgo f
salmon sperm non-specific DNA and 1 ng of radio-labelled binding site as specified. 12 mg of cell protein extract from a transfection of CMVOct-1RR plasmid
was also used in these EMSA experiment. EMSA experiments are representative of duplicated experiments. Oct-1/1RR and Oct-4/4RR/4N-R probe complexes are
indicated.CLreferstoextractsfromtransfectionsofemptyvector(EFplink)control.Bandsthatareboxedweredemonstratedbysubsequentcompetitionstudiestobe
non-specific.(E)Relativedifferencesinbindingaffinitybetweenaltered-specificityandwild-typebindingsystemswerederivedfromtriplicatecompetitionEMSA
experiments and are illustrated using a representative set of data. As specified in Materials and Methods, fixed concentrations of Oct-4 and Oct-4RR cell protein
extract,normalizedforOct-4-typeproteinconcentrationaccordingtowesternblotdata,wereusedwith1ngofH2BorVkGGlabelledproberespectivelyandarange
ofnon-labelledselfcompetitoroligonucleotide(2.5–40ng).AllcompetitionEMSAreactionscontained2mgpoly(dI–dC)competitorDNA.Bandintensityrelatingto
Oct-4:H2B/Oct-4RR:VkGGcomplexeswasmeasuredasaproportionof1(P-values;avalueof1beingattributedtobandintensityforbindingreactionswith2.5ng
selfcompetition).1minusP-valueswereplottedagainsttotaloligonucleotideusingGraphPad(PrismLtd)softwarepackage.KMreferstorelativebindingequilibria.
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ubiquitously. Phage display and GST-pull down data indicate
that Oct-4 interacts directly with the ubiquitous high mobility
group protein HMG-1, which cooperates with Oct-4 to some
degree to activate transcription in P19U cells (25). The same
study indicated that HMG-1 and two other minor Oct-4 inter-
acting proteins were unlikely to account for an apparent undif-
ferentiated P19 (P19U) cell-speciﬁc Oct-4 transactivity. Oct-4
has also been shown to directly interact with a single pluri-
potent cell-speciﬁc protein, FoxD, in GST-pull down assays
(26), although in this case Oct-4 functions as a weak core-
pressor, affecting FoxD transactivity in FoxA1/FoxA2 pro-
moters. In this case, FoxD was not implicated as a factor
which regulates Oct-4 activity on Oct-4 target promoters
and as such is not a realistic candidate for a cell-speciﬁc
Oct-4 cofactor. Moreover, an alternative interpretation for
such Oct-4-mediated repression is that over-expression of
Oct-4 to high levels leads to general transcription repression,
perhaps through squelching of general transcription factors or
other non-speciﬁc phenomena. This effect is also noted for
Oct-4 both in this current work and in data from other
studies (15).
Bearing in mind the importance of an intact protein for
proper Oct-4 function, studies here focused on minimal modi-
ﬁcations to the Oct-4 binding domain that altered its sequence
speciﬁcity to allow recognition of a custom bindingsite, which
itself was not effectively bound by wild-type POU proteins,
while maintaining a wild-type binding conformation. Thus,
a relevant and essentially ‘stand-alone’ assessment of Oct-4
transactivation function could be made.
An important ﬁrst step in this work was to demonstrate that
the altered-speciﬁcity system originally used in the study of
Oct-1 function would translate to an Oct-4 based system.
Binding analysis clearly showed that endogenous Oct-4 did
Figure 2. VkGT altered-specificity binding site displays a weaker enhancer function than VkGG. (A) Target constructs are detailed. The 6W sequence is derived
fromGersteretal.(34).(B)and(C)UndifferentiatedP19cellsweretransfectedwithspecifiedplasmids.Atotalof3.7mgDNAwasusedineachreactionusingempty
EFplink plasmid for normalization. 100 ng of reporter plasmid was used in each transfection and 100 ng of expression vector (EFOct-4/Oct-4N-R/Oct-4RR) unless
otherwise specified. CAT assays were subsequently performed on sample extract normalized for b-gal activity within an experiment. Data presented here are
representativeofexperimentsperformedintriplicate.(C)Forarepresentativeexperiment,ESMAwasperformedonwholecellextractmadefrom20%ofcellsfrom
transfection of pBLCAT only. Polyclonal rabbit anti-mouse Oct-4-specific antibody was used in EMSA supershift experiments.
6018 Nucleic Acids Research, 2005, Vol. 33, No. 18not bind signiﬁcantly to the VkGG site, whereas the Oct-4RR
proteinboundrelativelystronglytothissequence, indeedmore
strongly than reported for Oct-1RR mutants in similar studies
(16) and with only a slight drop in binding afﬁnity compared
with wild-type Oct-4 for the consensus octamer motif. Such
differences between related factors, however, may be a con-
sequence of general differences in binding afﬁnity between
Oct-4andOct-1(27),orasaconsequenceofusingcellextracts
rather than recombinant protein. For example, Oct-4 is shown
to bind as a dimer on the composite osteopontin PORE
enhancer using cellular extracts, but not using recombinant
protein (28).
In line with binding data, endogenous wild-type Oct-4 or
transiently expressed Oct-4 was unable to activate episomal
Figure 3. Oct-4RR has equivalent transactivation potential in undifferentiated and differentiated cellular environments. Undifferentiated P19 (P19U) cells or P19
cells induced to differentiate with 0.5 mM RA for 4 days (dP19 cells) were transfected with specified plasmids. (D and E) Reporter plasmid was transfected at
120 and 60 ng for P19U and dP19, respectively. Extract protein concentration was measured and half as much total protein was used in experiments for dP19 than
P19U. Fold activation refers to the proportional increase in reporter gene expression in response to Oct-4RR, relative to the basal transcriptional activity of
reporter vector alone. Averages and standard errors are shown for experiments repeated three times. Internal control b-gal readings, like CAT activity, seen at the
higher end of Oct-4RR expression vector concentrations were seen to be depressed, probably due to squelching of transcription associated molecules or as a
consequence of large amounts of mRNA overwhelming the translation process. As such, b-gal data were not used to normalize CAT experiments, but rather
plotted as a separate set of representative readings for reference. Asterisk indicates over 40-fold activation of reporter gene. (E) For experiments using wild-type
Oct-4, b-gal readings are used to standardize transcription levels. (A and B) For two of the three experiment repetitions, 20% of transfected cells were used to
make whole cell extracts for EMSA and western blot experiments in (A and B). (A) An aliquot of 100 mg of protein extract was included in western blot using
the anti-myc antibody against the epitope translated at the N-terminus of Oct-4RR. The predicted Oct-4 band of 38–40 kDa is shown. A blot control protein for
loading and transfer normalization is shown and represents endogenous protein cross-reacting with antibody used. (B) Each EMSA reaction included 20 mgo f
protein extract, specified probe binding site and 1 mg of poly(dI–dC) as non-specific competitor. (C) Following a separate set of transfection experiments using
specified plasmids, western blots were performed using antiOct-4 antibody and EMSA experiments undertaken to examine wild-type Oct-4 binding to consensus
octamer site in the H2B element. At 1 mg of expression vector, bound and free Oct-4 protein extract levels in dP19 cells were approximately twice that of
endogenous Oct-4 levels in P19U cells. After transfection efficiency is taken into account, cellular Oct-4RR concentrations at 250–500 ng levels of expression
vector were predicted to be approximately equivalent to endogenous Oct-4 levels in both cell types.
Nucleic Acids Research, 2005, Vol. 33, No. 18 6019reporter gene expression from upstream VkGG binding sites,
whereas transient expression of Oct-4RR lead to signiﬁcant
upregulation of this reporter gene construct. Maximum activa-
tion of reporter gene expression by Oct-4RR from upstream
target sites was not signiﬁcantly different between undiffer-
entiated embryonic carcinoma cells (P19 cells), where Oct-4 is
normally expressed, and differentiated P19 cells where Oct-4
expressionisnolongerseen. Moreover,astherewasnoindica-
tion of any signiﬁcant trend of enhanced Oct-4RR trans-
criptional activity speciﬁc to undifferentiated cells over a
wide range of cellular protein concentrations, and which
cover physiological Oct-4 concentrations, then it is unlikely
that Oct-4RR has any cell-speciﬁc activity through the VkGG
reporter construct. This result is in clear contrast to published
evidence and our own observations, which show wild-type
Oct-4 is responsible for a signiﬁcantly higher level of tran-
scriptional activation in undifferentiated EC cells compared
with differentiated cells, through consensus octamer binding
sites (1,7).
The altered-speciﬁcity binding site is based on the Igk light
chain promoter, which does not possess any consensus tran-
scription factor binding sites other than the mutant octamer
motif.The6Welementusedpredominantly inpreviousstudies
of Oct-4 cell-speciﬁc activity, however, contains a wild-type
Figure 4. A extended series of Oct-4RR N-terminus deletions were made on Oct-4RR with or without C-terminus.
Figure 5. Oct-4RR N-terminal and C-terminal domain truncations exhibit a similar pattern of transcriptional activity in P19, dP19 and NIH3T3 cells.
(A) Undifferentiated P19 cells or P19 cells induced to differentiate with 0.5 mM RA for 3 days and NIH3T3 cells were transfected with specified plasmids.
Reporter vector wasincluded at 120, 60 and 250 ng for P19U,dP19 and NIH3T3, respectively, and 250 ng and 1mg of Oct-4RR and Oct-4-based plasmids wasused
in transfections of P19 and NIH3T3 cells, respectively. Cells were harvested after 48 h post transfection and cell extracts for CAT assays and EMSA experiments
were made from 70 and 30% of cells, respectively. Data are representative of experiments repeated three times and the mean values of at least two independent
transfection experiments are plotted. Fold activation refers to a multiple of background CAT activity seen for reporter vector. Internal control b-gal readings were
used to standardize transfection efficiency and protein expression/binding is assessed in (B and C). Western blots were performed against the translated
myc epitope in B using 100 mg of nuclear protein extract and used to balance protein input in EMSA experiments in (C, i). For wild-type protein binding
in (C, ii), 20 mg of protein extracts are used directly in EMSA experiments.
6020 Nucleic Acids Research, 2005, Vol. 33, No. 18octamer motif which is a target for Oct-1 and Oct-6 as well as
Oct-4, and has adjacent binding sites for bHLH transcription
factors (7–9,15). As such, the 6W enhancer allows multiple
factor interactions that could potentially modulate Oct-4 bind-
ing afﬁnity or activity. Interestingly, a 6W element lacking a
functional bHLH binding site and a H2B promoter element,
which contains a consensus octamer motif only, both show a
signiﬁcantly lower activity in undifferentiated P19 cells than
the intact6Welementandarenotactivatedatallbyexogenous
Oct-4 in differentiated P19 cells (data not shown). This sug-
gests a fundamental involvement of the bHLH site in regu-
lating Oct-4 function, but still points towards a cell-speciﬁc
regulation of Oct-4 to some degree. However, no evidence of
proteins binding bHLH sites was seen here or elsewhere [(29)
and data not shown]. As such, the relationship between Oct-4
and the bHLH binding site in the 6W element remains
unknown.
One explanation as to why no cell-speciﬁc Oct-4RR activity
is seen in these studies compared to wild-type Oct-4, is that
other POU proteins may ordinarily contribute to/interfere with
wild-type Oct-4 function when bound to octamer motif them-
selves. For example, it has been shown that Oct-4 can be
recruited to promoters by Oct-1, with a positive effect on
transcription activation (29). In this respect, it is interesting
to note that our binding data suggests higher levels of Oct-1
binding to H2B octamer motif for undifferentiated P19 cells
than differentiated cells (Figure 3B). An alternative model for
the regulation of Oct-4 function is a direct competition
between Oct-1 and Oct-4 for octamer site binding. Oct-4 tran-
scriptional activation studies by several laboratories indicate
that cellular Oct-1 does not activate transcription through
octamer motif DNA to a signiﬁcant degree when compared
with Oct-4 in differentiated cells (1,2,7,17,30). Thus, if Oct-1
has a different distribution, binding proﬁle or transcription
regulation capability between different cell states, this
would translate to an apparent cell-speciﬁc Oct-1 repres-
sion/enhancement of Oct-4 transactivation in differentiated/
undifferentiated cells, respectively. A recent investigation into
Oct-1 nuclear localization in Xenopus embryos showed that a
higherlevel of Oct-1 proteinlocalizedtothe nucleus following
cell differentiation, possibly supporting the repression model
of Oct-4 regulation (31). However, no such evidence for an
Oct-1 cell-speciﬁc distribution pattern was seen here using
whole cell or nuclear protein extracts, although distribution
differences that are particular to a speciﬁc cell-cycle stage or
due to nuclear compartmentalization are unlikely to be picked
up in such assays.
Deletion studies allowed P19U cell-speciﬁc activation
domain usage to be detected that might have been masked
in studies using full-length protein, due for example to a gen-
eral non-speciﬁc Oct-4RR transactivity that is particular to
differentiated cells. Consistent with studies of intact Oct-
4RR protein, no cell-speciﬁc activation domain usage was
noted here. Accordingly, any cell speciﬁcity attributed to
Oct-4mustbeafunctionofthewild-typePOUdomain binding
conformation or binding site context.
The N-terminus was shown to be the predominant Oct-4RR
activation domain with the C-terminus exhibiting a lower but
still signiﬁcant transactivity. This result was consistent with
the ﬁndings of Niwa et al. (13), who indicate that the Oct-4
C-terminus can complement deletion of the N-terminus, and
viceversa,tomaintainthe Oct-4-dependentpluripotentpheno-
type. The transactivation function of the N-terminus required
amino acids 30 to 70. Such a ﬁnding has previously been seen
Figure 6. Extended deletions of Oct-4RR N-terminal show no cell specificity for transcriptional activity. (A) Undifferentiated P19 cells or P19 cells induced to
differentiate with 0.5 mM RA for 3 days were cotransfected with 250 ng of specified Oct-4RR plasmids and pVkGG11CAT reporter plasmid (reporter plasmid was
transfected at 120 ng for P19U and 60 ng for dP19 throughout). p6WCAT reporter plasmid was also used in control transfection experiments were specified. Cells
wereharvestedafter48hposttransfectionandwholecellextractsmadeforCATassays.CATassaysweresubsequentlyperformedonsampleextractnormalizedfor
b-galactivitywithinanexperimentforeachcelltype.Figureisrepresentativeofdatarepeatedatleastthreetimeswithaveragesandstandarderrorsshown.(BandC)
In parallel transfection experiments using 1 mg of specified expression vectors, nuclear protein extracts were made and western blots were performed against the
translated myc epitope. Blots are representative of duplicated data.
Nucleic Acids Research, 2005, Vol. 33, No. 18 6021to a limited degree using Oct-4 N-terminus:c-Jun fusion pro-
teins in P19U cells and a reporter based on the c-Jun binding
site (1,32). As such, this shows that the Oct-4RR POU and
c-Jun binding domains maintain the same functional relation-
ship between the Oct-4 N-terminus and the general transcrip-
tion machinery to some degree. However, data for the Oct-4
N-terminus:C-Jun fusion protein studies indicates that amino
acids 1–36 are needed for complete N-terminus function
whereas we show that deletion of amino acids 2–29 from
Oct-4RR has little or no effect on protein transactivation func-
tion. As no obvious functional motifs are apparent between
amino acids 29 and 36, then the conﬂicting results seen
between c-Jun and Oct-4RR N-terminal deletion studies
may point to an inter-regulatory function between the Oct-4
N-terminus activation domain and Oct-4 binding domain,
which is abrogated when the c-Jun binding domain is used
to target the N-terminus to a promoter. As introduced earlier,
such a speciﬁc dependence for the Oct-4 POU domain has
been previously noted for the Oct-4 C-terminus activation
domain which was shown to display a HeLa cell-speciﬁc
activity from 6W enhancer DNA only when linked to its
cognate binding domain (15).
In conclusion, the results presented here demonstrate that an
altered-speciﬁcity binding Oct-4 protein can be successfully
used in transactivation studies in an Oct-4-native environment,
without interference from wild-type octamer factors, while
maintaining the characteristics of promoter-bound wild-type
protein. Using this system, we have been able to show that
Oct-4 has an equivalent transactivation function in pluripotent
and differentiated cellular environments when presented as a
stand-alone transcription factor. These results therefore cast
doubt on a previously postulated pluripotent cell-speciﬁc
Oct-4 function on equivalent wild-type promoters that is
gained through the recruitment of an unknown E1A-like tran-
scription cofactor speciﬁc to these cells. We now propose that
an observed Oct-4 cell-speciﬁc activity may be the product of
additional binding of transcription factors, such as Oct-1, that
either interfere with or modulate Oct-4 activity and which
themselves have either a different distribution or activity
between cell types. These results should provide further
insight into the functional attributes of Oct-4, and its role in
stem cell biology.
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